Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAd3-EBO-Z in Adults in Africa
NCT02485301Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2015
- Primary completion
- Dec 2016
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of ChAd3-EBO-Z in Ebola virus disease (EVD), sponsored by GSK. Started Jul 2015; status: completed.
02
Drugs
ChAd3-EBO-Z
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02485301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485301.